Blue Cross Blue Shield NM dispensing limits Policy Update | OpenPayer
CurrentBlue Cross Blue Shield - New MexicoPolicy N/A
Balanced Biosimilar Dispensing Limits (DL)
Defines quantity and time-period dispensing limits for covered biologic and biosimilar drugs under BCBSNM pharmacy benefits and explains member cost responsibility when prescriptions exceed limits. Applies to members whose benefits reference these dispensing limits and to pharmacies/providers dispensing these drugs.
Policy Summary
PayerBlue Cross Blue Shield - New Mexico
PolicyBalanced Biosimilar Dispensing Limits (DL)
Policy CodePolicy N/A
Change TypeNo material changes
Effective DateN/A
Next Review DateN/A
Key ActionVerify member benefit materials or call the number on the back of the member ID to confirm plan-specific dispensing limits and exclusions.
No material clinical or coverage changes in this revision.
multiplelisted drugs with dispensing limits in this segment
per 28 / 30 / 180 daystypical time-periods used for limits
mostentries include dispensing limit and BG/B/G preference
BCBSNMplan / payer referenced
~120+distinct drugs/products listed in excerpt
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
Coverage criteria and dispensing limits
Drug-specific dispensing limits
Covered drugs are subject to the specific dispensing limits listed below (quantity per time period).
Drug-specific dispensing limits: Each listed drug is covered only up to the Dispensing Limit shown for that product presentation (quantity + time period). Examples: abacavir sulfate solution 20 mg/mL — 960 mL per 30 days; abacavir sulfate 300 mg — 60 tablets per 30 days; abatacept (Orencia Clickject) — 4 syringes per 28 days; adalimumab prefilled syringe/pen presentations — commonly 2 pens or 2 syringes per 28 days or starter kit limits per 180 days.per-line quantities
See product entries for the exact per-product limit and BG/B/G designation.
Product-specific quantity limits
Covered when dispensing does not exceed the listed per-period quantity for the specific product presentation and follows the brand/generic designation.
Per-product dispensing limit: For each product presentation, coverage is limited to the exact Dispensing Limit and period listed (for example, many adalimumab auto-injector presentations = 2 Pens Per 28 DAYS; many prefilled syringe presentations = 2 Syringes Per 28 DAYS; some starter kits = 1 Kit Per 180 DAYS).per-line quantities
Brand/generic flag (BG/B/G) on each line indicates allowed product types.
Antihemophilic factor dispensing
Coverage for antihemophilic factor products is dependent on individualized dosing.
Weight- and dose-dependent dispensing: Antihemophilic factor products (recombinant and human-derived) list limits as mL Per 30 DAYS or state 'Dependent on patient weight and number of doses'; coverage requires calculation of per-patient volume based on weight and prescribed dosing schedule.dependent on patient weight and dosing
Refer to product kit/unit entries for the reported mL per 30 days and perform individualized dose calculation for coverage.
General coverage criteria
Covered when dispensed within the listed product-specific limits and in accordance with the brand/generic preference flag.
General coverage requirement: Dispensed quantity must not exceed the product-specific Dispensing Limit for the stated time period (e.g., per 28 days, per 30 days). The BG/B/G designation on each line indicates whether Brand and Generic (BG), Brand only (B), or Generic only (G) formulations are permitted for that entry.see product entries
Some entries (notably factor products) include weight- or dose-dependent notes.
Per-product dispensing limits
Coverage is permitted up to the listed dispensing limit for each listed product and formulation.
Azithromycin: Dispensing Limit = 60 Tablets Per 180 DAYS; QL cumulative across strengths; designation = BG.60 tablets/180 days
chunk 54
Aztreonam lysine for inhalation (Cayston) 75 mg: Dispensing Limit = 84 mLs Per 56 DAYS (1 kit = 84 vials = 84 mL); designation = B.84 mL/56 days
chunk 54
Belimumab (Benlysta) subcutaneous: Dispensing Limit = 4 Syringes Per 28 DAYS; designation = B/BG.4 syringes/28 days
chunk 56
Standard dispensing limits (per-product)
Covered when dispensing quantity does not exceed the listed limit for the product
Standard per-product rule: Dispensed quantity must be less than or equal to the product-specific Dispensing Limit for the stated time window (examples in the list include clobetasol cream 0.025% = 100 grams per 30 days; clindamycin phosphate solution 1% = 180 mLs per 30 days).per-product limits as listed
Some topical agents and others indicate cumulative limits across agents or strengths.
Dispensing limits (per-product)
Covered when claims adhere to the listed dispensing limits and brand/generic designation for each product.
Product-level dispensing rule: Each product entry defines an allowed Dispensing Limit (quantity and time period) and a BG/B/G designation; coverage requires dispensing within that limit and appropriate product type (brand vs generic).per product entry
See product lines in the policy for exact limits and designations.
Quantity-limited coverage
Covered when dispensing does not exceed the listed per-product limits
Per-product quantity compliance: Pharmacy dispensing must be within the specified quantity and day period for the exact product formulation listed (examples: emtricitabine formulations — 30 capsules per 30 days or liquid mL limits; enfuvirtide 60 vials per 30 days; ensifentrine 60 ampules per 30 days).per-item limits as listed
Brand/generic designation applies per line.
Per-product dispensing limits
Coverage of pharmacy-dispensed products is limited to the following maximum quantities per specified time period:
Fluticasone furoate-vilanterol (Breo Ellipta): Dispensing Limit = 1 Inhaler Per 30 DAYS (60 blisters = inhaler = 30 doses).1 inhaler/30 days
chunk 126
Flovent Diskus 100 mcg: Dispensing Limit = 60 Blisters Per 30 DAYS (60 blisters = inhaler = 60 doses).60 blisters/30 days
chunk 126
Flovent Diskus 240-blister SKU: Dispensing Limit = 240 Blisters Per 30 DAYS (240 blisters = 4 inhalers = 240 doses).240 blisters/30 days
chunk 127
General dispensing limit criterion
Covered when dispensing does not exceed the listed product-specific quantity limits
Product-level quantity compliance: Dispensed quantity must be less than or equal to the product's listed Dispensing Limit for the specified period (examples: many insulin products = 100 mLs per 30 days; insulin pen needles/syringes = 300 Units per 30 days cumulative).per-product limits as listed
Pen needles/syringes and injectable formulations often specify QL cumulative across related SKUs.
Quantity-limit compliance
Coverage is allowed when dispensing does not exceed the specified product-level quantity limits and matches the indicated brand/generic designation.
Per-product QL compliance: Dispensing must be ≤ the listed quantity limit for the specific product (examples: insulin syringes — 300 Units per 30 days cumulative; Betaseron — 14 vials per 28 days; Rebif/Rebidose — 12 syringes per 28 days; ixekizumab — 1 syringe per 28 days; lenacapavir — 4 tablets per 365 days).see individual product entries
QLs are cumulative where stated (e.g., across insulin syringes).
Dispensing limits (by product/formulation)
Coverage is limited to the specified dispensing quantities per product/formulation as listed below.
Ledipasvir‑sofosbuvir 90/400 mg: Dispensing Limit = 28 Tablets Per 28 DAYS.28 tablets/28 days
chunk 180
Lemborexant 5/10 mg (Dayvigo): Dispensing Limit = 30 Tablets Per 30 DAYS; QL cumulative across agents.30 tablets/30 days
chunk 180
Lenacapavir 300 mg (Sunlenca/Yeztugo): Dispensing Limit = 4 Tablets Per 365 DAYS (annual pack limits shown).4 tablets/365 days
chunk 180-181
Product-specific dispensing limits
Covered when dispensing does not exceed the listed limit and product type matches BG/B/G designation
Maraviroc 75 mg (Selzentry): Dispensing Limit = 60 Tablets Per 30 DAYS; product flag = B.60 tablets/30 days
chunk 198
Mepolizumab (Nucala) 100 mg syringe: Dispensing Limit = 3 Syringes Per 28 DAYS; product flag = B.3 syringes/28 days
chunk 204
Paxlovid (nirmatrelvir/ritonavir) pack: Dispensing Limit = 20 Tablets Per 90 DAYS (pack-level limits); product flag noted per listing.20 tablets/90 days
chunk 204
Per-formulation dispensing limits
Covered when dispensing does not exceed the listed quantity limit per period and matches brand/generic designation
Quetiapine fumarate examples: Quetiapine fumarate 100 mg: Dispensing Limit = 60 Tablets Per 30 DAYS; designation = BG. Other quetiapine strengths have specific per-30-day limits per line.per-strength limits as listed
chunk 234
Raltegravir (Isentress) chewable: Dispensing Limit = 180 Tablets Per 30 DAYS for chewable 100 mg; other formulations have specified limits.180 tablets/30 days
chunk 236
Risankizumab (Skyrizi Pen): Dispensing Limit = 1 Pen Per 84 DAYS; designation = B.1 pen/84 days
Standard dispensing limits
Covered when dispensing quantity does not exceed the listed product-specific limit
General product-level rule: Dispense quantity must be ≤ the product-specific limit (examples include sodium oxybate 540 mL per 30 days; siponimod 30 tablets per 30 days). Brand/generic flags indicate allowed sourcing but do not alter the numeric limit.per-product limits as listed
See listed product lines for exact numeric limits.
Cumulative quantity rules
Covered when class cumulative limits are not exceeded
Oral triptan cumulative limit: Total oral triptan quantity across all oral triptan agents must not exceed 18 tablets per 30 days.<= 18 tablets per 30 days
Cumulative across agents as stated in multiple entries (e.g., eletriptan, frovatriptan, sumatriptan).
Tadalafil cumulative dosing guidance: Certain tadalafil dosing entries note an 8-dose-per-30-days cumulative rule for on‑demand dosing patterns; apply cumulative counting across tadalafil products where specified.<= 8 doses per 30 days where specified
See tadalafil entries for cumulative dosing language.
Dispensing limits in this listing are administrative controls that may not apply uniformly to every member. Limits may vary by state law or by the member's specific benefit plan; some plans or lines of business may exclude coverage for particular agents or drug categories (for example, certain erectile dysfunction agents) or restrict site-of-care (mail service vs retail). Verify the member's benefit materials or call the number on the back of the member ID to confirm applicability of any listed limit or exclusion.
Dispensing that exceeds the stated quantity/timeframe limits, or dispensing a product that is not permitted by the plan's brand/generic designation (for example dispensing a non‑preferred brand when the entry indicates Generic Only or vice versa), may affect coverage and adjudication. Claims that exceed line-item dispensing limits are subject to claims edits and may require prior authorization or be denied.
Coverage under these rules is limited to the numeric per‑product dispensing limits shown. No coverage is provided beyond the specified per‑product quantity limits unless a separate override, prior authorization, or other payer policy explicitly authorizes additional supply.
Within the excerpt provided there are no explicit clinical exclusion conditions listed; the policy text and tables emphasize product‑level dispensing quantity limits and BG/B/G brand/generic designations rather than clinical contraindications or diagnoses.
Quantity claims that would cause cumulative class limits to be exceeded (for example the oral triptan cap of 18 tablets per 30 days across all agents) are implicitly outside the allowable dispensing and may be excluded from coverage under these dispensing limits.
Products that do not meet the listed quantity or day‑supply specification for the line item (for example pen‑needle or syringe entries that are limited to a stated number of units per 30 days) are not consistent with the dispensing limits and may be excluded or adjusted at claim adjudication.
No additional explicit exclusions are documented in the provided excerpt beyond the numeric dispensing limits; where exclusions exist they are typically expressed as a failure to meet the listed dispensing allowance.
The excerpt does not list clinical exclusion criteria beyond numeric dispensing caps. Entries dispensed above the stated limits are implicitly outside standard coverage unless otherwise authorized.
No explicit clinical exclusion statements appear in these chunks; the module enforces per‑product and formulation quantity limits (grams, mLs, tablets, pens, syringes) as the controlling coverage constraint.
There are no clinical exclusion conditions described in this excerpt. The policy functions by setting per‑period dispensing limits for each listed product or formulation and by indicating brand/generic preference where applicable.
This excerpt does not list explicit clinical exclusion conditions beyond the numeric limits; entries that exceed stated dispensing allowances or violate brand/generic designations are treated as non‑standard and may require prior authorization or be denied.
Amounts that exceed the specified per‑period dispensing limits or that violate cumulative limits across agents (for example oral triptans > 18 tablets per 30 days) are outside the listed allowances and may be excluded from coverage unless an override is granted.
No explicit clinical exclusions are stated in the referenced chunks. The coverage constraints shown are expressed as numeric dispensing limits per product/formulation and brand/generic flags rather than diagnosis‑based exclusions.
Dispensing quantities that exceed the listed limits without documented clinical justification or an approved override are not supported by this list and may be considered non‑covered under the standard dispensing limit policy.
Not specified in the provided excerpt; the document focuses on administrative quantity limits per product rather than listing additional exclusion language in these chunks.
Dispensing quantities that exceed specified limits (for example many insulin products limited to 100 mLs per 30 days, or insulin syringes/pen needles limited to 300 units per 30 days) are treated as outside the listed dispensing allowances and may be considered not covered unless prior authorization or a separate policy allows additional supply.
No explicit 'not medically necessary' statements are present in these chunks; the policy uses numeric dispensing limits as the administrative coverage control rather than formal medical‑necessity language in this excerpt.
None explicitly stated in the provided excerpt. Where 'not medically necessary' determinations apply, they would be driven by payer processes outside the numeric dispensing limits shown here.
Product listings and code mappings
What providers and pharmacies must do
Prior Authorization
Provider Actions — Dispensing limits and prior authorization expectations
This policy defines product-level dispensing limits that pharmacies and providers must follow. Dispensing limits may be fixed per product or based on patient-specific factors (for example, weight-dependent dosing for certain clotting factor and biologic products). When a prescription exceeds a listed dispensing limit, when a non-preferred or brand-only specialty product is requested, or when a dispensing interval extends beyond the stated frequency, prior authorization (PA) or an override may be required. Verify member benefit materials or contact the number on the member ID card to confirm plan-specific limits, exclusions, and any PA processes.
Adhere to product-level dispensing limits shown in the DL list (units and time window).
Weight-dependent dosing entries: some products (notably clotting factor and other weight-based biologics) list dispensing limits as dependent on patient weight and number of doses; calculate allowable quantity based on documented patient weight and dosing schedule.
Quantity specification: limits are expressed in product-specific units (tablets, pens, syringes, mLs, inhalers, cartridges, packs, kits, vials, doses) and a defined time period (Per 28 DAYS, Per 30 DAYS, Per 90 DAYS, Per 365 DAYS, etc.).
Cumulative quantity limits: certain classes are cumulative across strengths or agents (examples: oral triptans, desoximetasone family, insulin syringes); total claims must not exceed the cumulative limit.
Dispense to specified units: pharmacies should dispense the exact units referenced (e.g., blisters, pens, syringes, cartridges, vials) and may not substitute unit packaging without authorization.
SourcePolicy line: abacavir sulfate soln 20 mg/mL — 960 mLs per 30 DAYS
abacavir sulfate tab 300 mg
Productabacavir sulfate tablets 300 mg (Ziagen)
Dispensing limit60 Tablets Per 30 DAYS
SourcePolicy line: abacavir sulfate tab 300 mg — 60 tablets per 30 DAYS
Biosimilars and branded biologic presentations
Note
Note
Note
Note
Note
Note
Maintenance and continuation dispensing guidance
Maintenance biologics
Ongoing maintenance dispensing limits for biologics and specialty injectables are expressed per period.
Maintenance biologics (example: belimumab subcutaneous 200 mg syringes/pens) are limited to the per-period quantities listed (e.g., belimumab = 4 syringes per 28 days). Coverage for continuation is contingent on adherence to these per-period limits.per-product maintenance limits
See biologic entries for specific maintenance limits (pens/syringes per 28/30 days).
Site of care and dispensing channel notes
Note
Key definitions used in this policy
Step therapy / starter kit guidance
Kit type
Dispensing limit
Coverage note
Starter kit
1 kit per 180 days
Covered when dispensed no more than 1 starter kit per 180 days; exceeding limit may require prior authorization or be denied
Maintenance kit
2 kits per 28 days (typical)
Covered when maintenance kits are dispensed within the listed per-28-day limits; quantities beyond the listed maintenance limit may require prior authorization
Note
Note
Note
Background and policy intent
Background: Dispensing limits are administrative limits intended to align medication dispensing with FDA‑approved use and plan design (for example limiting specialty medications to a 30‑day supply in many plans). These limits control the permitted quantity of a covered medication per prescription or over a specified time window and do not themselves establish clinical efficacy or detailed medical‑necessity criteria.
Policy Summary
PayerBlue Cross Blue Shield - New Mexico
PolicyBalanced Biosimilar Dispensing Limits (DL)
Policy CodePolicy N/A
Change TypeNo material changes
Effective DateN/A
Next Review DateN/A
Key ActionVerify member benefit materials or call the number on the back of the member ID to confirm plan-specific dispensing limits and exclusions.
Bimekizumab (Bimzelx): Dispensing Limit = 2 Pens or 2 Syringes Per 56 DAYS (160 mg/mL) or 1 Pen Per 28 DAYS (320 mg); designation = B.1-2 pens/28-56 days
chunk 55-56
chunk 236-238
Required claim adherence: pharmacy claims must reflect the product, formulation/strength, quantity dispensed, and day supply consistent with the listed dispensing limit and brand/generic preference flag.
Match formulation/strength: claims and documentation must match the formulation and strength listed; dispensing limits apply per listed formulation/strength unless cumulative rules specify otherwise.
Dispensing documentation: pharmacies should document product, quantity dispensed, date ranges, and the applicable time window to support claims and overrides.
Documentation tied to listed dispensing limits: ensure prescription records and claim submissions demonstrate compliance with per-period dispensing limits and any cumulative rules across agents.
Required claim information: include product identifier, NDC or other code as applicable, dispensed quantity, and day supply consistent with the DL entry.
Claim-level documentation and claim-level quantity documentation: maintain records showing how the dispensed quantity falls within the DL period and any cumulative calculations used.
Quantity and cumulative limit adherence: when a DL indicates cumulative limits across strengths or agents, ensure combined dispensing across those products does not exceed the stated maximum.
Coverage limit overage: if a prescriber authorizes a quantity beyond the dispensing limit and the claim is paid without PA, the member may be responsible for costs above coverage limits; otherwise claims exceeding limits may be denied.
Quantity limit exceedance / Exceeding dispensing limits: requests that exceed listed dispensing limits may be rejected at point of sale or require a quantity limit override or PA; repeated noncompliance may result in denials.
Quantity limits are primary control: DLs are the main mechanism controlling covered quantities; absence of an explicit PA statement does not guarantee coverage beyond the DL.
Quantity limits only — PA not specified: for many products the DL defines coverage without an accompanying PA requirement; in those cases standard claims edits enforce the limit.
PA when limits exceeded or non-preferred product dispensed: prior authorization may be required when dispensing limits are exceeded, when a non-preferred/brand-only product is dispensed, or when the requested product is a high-cost specialty biologic.
Prior authorization for specialty biologics / Specialty/brand product authorization: certain specialty or biologic products have low per-period dispensing limits and brand-only designations; these commonly require the standard pharmacy PA process before coverage will be approved.
Prior authorization for quantities above limits / Prior authorization for quantities above listed limits / Prior authorization for quantities above Dispensing Limit: prescribers must submit PA documentation to justify quantities beyond DLs; supporting clinical information and dosing rationale should be provided.
Prior authorization may be required if exceeding listed limits: when clinical need warrants quantities above the DL (including multi-month starter packs or extended-interval therapies), submit a PA with justification — absence of timely PA may lead to denial.
Prior authorization for extended intervals: some agents have annual or multi-month dispensing limits (e.g., agents limited Per 365 DAYS); obtaining coverage for additional dosing frequency or quantity typically requires PA.
Dispensing-limit enforcement / Dispensing-limit enforcement: multi-month pack or low-frequency dispensing is enforced by claims edits and may require PA or manual review to override.
Quantity limit enforcement / Quantity limit noncompliance: dispensing beyond listed per-period quantity limits may trigger denial or require an override; document any exceptions and PA approvals to prevent retrospective denials.
Cumulative triptan quantity limit: for oral triptans and triptan combinations the maximum is cumulative (example: 18 tablets per 30 days across all agents); ensure combined fills across agents adhere to this cap.
Cumulative desoximetasone quantity limit: topical desoximetasone entries include cumulative limits across the desoximetasone family (e.g., 100 g per 30 days across agents); monitor cumulative dispensing across formulations.
Claims must match listed dispensing limits: submit claims consistent with DL entries; mismatched day supply, units, or strength may trigger denial or edit.
Benefit verification: verify member-specific benefits or call the phone number on the back of the member ID to confirm whether dispensing limits, exclusions, or state-specific variations apply.